# Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

> **NCT04886700** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Uterine Cervical Cancer

## Interventions

- **DRUG:** SG001

## Key facts

- **NCT ID:** NCT04886700
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886700, "Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04886700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*